Free delivery and 10ml BAC Water on orders over $200
$0.00
Free Shipping on All Orders Over $200
Semaglutide vs Tirzepatide vs Retatrutide in Research
Research use only
This article is for scientific context. Semaglutide, Tirzepatide and Retatrutide sold on this site are research-grade chemical reagents. They are not medicines, not TGA-approved for supply as therapeutic goods in this form, and not for human consumption, therapeutic use, diagnostic use or veterinary use.
In brief
These three synthetic peptides are used in laboratory research on incretin and glucagon receptor signalling. They differ mainly in which receptors they engage and in the structural features that produce that profile.
| Peptide | Receptor profile | Length | Molecular weight (approx.) | CAS |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | 31 aa | 4114 g/mol | 910463-68-2 |
| Tirzepatide | Dual GIP + GLP-1 agonist | 39 aa | 4813.5 g/mol | 2023788-19-2 |
| Retatrutide | Triple GIP + GLP-1 + glucagon agonist | 39 aa | 4731 g/mol | 2381089-83-2 |
A key paper describing the design of the triple agonist (Retatrutide, LY3437943) is Coskun et al., Cell Metabolism (2022):
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.
Semaglutide — single GLP-1 receptor agonist
Semaglutide is a 31-amino-acid peptide built on a modified GLP-1(7-37) backbone. It is used in research as a selective GLP-1 receptor (GLP-1R) agonist.
Key structural features:
- Alanine at position 8 replaced by α-aminoisobutyric acid (Aib) for proteolytic stability
- Lysine at position 34 replaced by arginine
- Lysine at position 26 acylated with a C18 fatty diacid via a γ-glutamate + AEEA linker (albumin-binding modification)
Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Typical research use: GLP-1R pharmacology, cAMP signalling assays, comparison against dual or triple agonists in the same panel.
PubChem record: CID 56843331.
Tirzepatide — dual GIP / GLP-1 agonist
Tirzepatide (LY3298176) is a 39-amino-acid peptide designed on a GIP backbone with modifications that confer balanced activity at both the GIP receptor (GIPR) and GLP-1R.
Key structural features:
- Two Aib residues (positions 2 and 13)
- C-terminal amide
- Lysine at position 20 conjugated to a C20 fatty diacid via a hydrophilic linker
Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Typical research use: Dual incretin receptor studies, head-to-head comparison with selective GLP-1R agonists, investigation of synergistic GIP + GLP-1 signalling in cellular and animal models.
Retatrutide — triple GIP / GLP-1 / glucagon agonist
Retatrutide (LY3437943) is a 39-amino-acid peptide that adds glucagon receptor (GCGR) activity to the dual GIP/GLP-1 profile. It is the first widely studied balanced triple agonist of this type.
Key structural features:
- Aib at positions 2 and 20
- α-methyl-leucine at position 13
- Lipidation at Lys17 with a C20 fatty diacid via linker
- C-terminal amide
Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Typical research use: Triple-receptor pharmacology panels, studies of energy expenditure pathways linked to GCGR, comparative work against dual agonists.
The design and early characterisation are described in the Coskun et al. Cell Metabolism paper.
Side-by-side research comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Primary receptors | GLP-1R | GIPR + GLP-1R | GIPR + GLP-1R + GCGR |
| Agonist class | Single | Dual | Triple |
| Length | 31 aa | 39 aa | 39 aa |
| Lipidation | C18 diacid at Lys26 | C20 diacid at Lys20 | C20 diacid at Lys17 |
| Non-coded residues | Aib (pos. 8) | Aib (pos. 2, 13) | Aib (pos. 2, 20) + α-MeLeu (pos. 13) |
| C-terminus | Free acid | Amide | Amide |
| Typical lab context | Selective GLP-1R reference | Dual incretin reference | Triple agonist reference |
Researchers choose among them according to the receptor set required for the assay. A selective GLP-1R experiment uses Semaglutide. A dual GIP/GLP-1 panel uses Tirzepatide. A triple panel that includes GCGR uses Retatrutide.
Laboratory applications
These peptides appear in:
- Receptor pharmacology and cAMP / calcium signalling assays
- Comparative studies of single vs dual vs triple agonism
- Cellular models of glucose handling and insulin signalling
- Animal metabolic models (institutional ethics approval required)
- Structural and binding studies of the respective GPCRs
They are supplied as lyophilised research reagents for reconstitution according to the experimental protocol. They are not pharmaceutical-grade injectable medicines.
Quality and documentation notes
For reproducible work, confirm each batch against:
- Expected sequence and modifications
- HPLC purity (typically ≥98% for research-grade material)
- Mass-spectrometric identity matching the stated molecular weight
- Batch-specific Certificate of Analysis
HPLC purity is not the same as net peptide content. Salt form and residual moisture affect the actual peptide mass in the vial. Use the CoA for concentration-critical work.
Regulatory note (Australia)
Unapproved peptide products are regulated as therapeutic goods if supplied or promoted for human use. A “research use only” statement does not make human supply lawful. These materials are sold only for laboratory research, with Australia-only shipping, to buyers who confirm research intent.
Sources
- Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00312-6 - PubChem Semaglutide: https://pubchem.ncbi.nlm.nih.gov/compound/56843331
